Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW031 vs placebo in postmenopausal osteoporosis
CTR20192015Phase 3Completed
- Sponsor
- Taikang Biopharmaceutical
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 9MW0311 in osteoporosis, sponsored by Taikang Biopharmaceutical. Started Nov 2019; status: completed.
02
Drugs
9MW0311
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20192015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192015.